Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma.

CONCLUSION: Bevacizumab 7.5mg/kg with cisplatin and gemcitabine was well tolerated. Promising tumour response was observed and supported mechanistically by positive effects on tumour perfusion and immune cell trafficking into the tumour.
PMID: 32816944 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 13, 2020 Category: Cancer & Oncology Authors: Chong WQ, Lim CM, Sinha AK, Tan CS, Chan GHJ, Huang Y, Barr Kumarakulasinghe N, Sundar R, Jeyasekharan AD, Loh WS, Tay JK, Yadav K, Wang L, Wong AL, Kong LR, Soo RA, Lau JA, Soon YY, Goh RM, Ho FCH, Chong SM, Lee SC, Loh KS, Tai BC, Lim YC, Goh BC Tags: Clin Cancer Res Source Type: research